Orion Oyj (HEL:ORNAV)

Market Cap	9.70B +27.1%
Revenue (ttm)	1.95B +22.9%
Net Income	529.40M +52.4%
EPS	3.76 +52.1%
Shares Out	n/a
PE Ratio	18.31
Forward PE	15.94
Dividend	1.80 (2.66%)
Ex-Dividend Date	Oct 19, 2026

Volume	7,072
Average Volume	10,295
Open	67.70
Previous Close	67.70
Day's Range	67.40 - 68.50
52-Week Range	54.20 - 75.10
Beta	0.27
RSI	47.15
Earnings Date	Apr 23, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Country: Finland
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.